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Passiflora cincinnata;Abstract The development of new drugs from plants is an interesting alternative approach to over-
coming microbial resistance. Passiflora cincinnata shows resistance to diseases and pests and a
higher concentration of chemical components that may be useful in the pharmaceutical industry.
We investigated the potential antimicrobial and antibiotic-modifying activity of hydroalcoholic
extracts of leaves, stems, bark, pulp and seeds of P. cincinnata. The extracts were prepared by
homogenization of material in 50% ethanol. Minimum inhibitory concentration (MIC) was deter-
mined by the broth dilution method, and the bacterial strains tested were Staphylococcus aureus ands, 1161,
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scherichia coli. Saudi Journal of BiologicalEscherichia coli. Antibiotic-modifying activity was evaluated against the strains S. aureus 03 and
E. coli 08, using a subinhibitory concentration of extract. The antibiotics tested were: amikacin, gen-
tamicin, ampicillin, potassium benzylpenicillin and oxacillin. The extracts did not show antimicro-
bial activity of clinical relevance, where the MIC was equal to or greater than 1024 lg/mL. S. aureus
showed 13 events, while E. coli showed only 4 events. Among these events, 14 involved synergistic
activity, potentiating the effect of the antibiotics, and only 3 events demonstrated antagonistic activ-
ity toward ampicillin. Hydroalcoholic extracts are potential antimicrobial agents when combined
with conventional drugs little utilized in in vivo treatment.
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open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The history of humanity, from the medical point of view, can
be considered a battle against infectious diseases. In the begin-
ning of the 21st century, the occurrence of bacterial infections
resistant to drugs became common and research to develop
new drugs with antimicrobial activity has spread to new clini-
cal areas (Harbarth and Samore, 2005; Chin et al., 2012).
Accordingly, natural products from plants are interesting
alternatives for solving this problem, since many plant extracts
and their phytochemical constituents are known to have
antimicrobial activities (Coutinho et al., 2009a). In the last
years, various studies in different countries have been con-
ducted aimed at demonstrating this efficacy (Gibbons, 2004;
Coutinho et al., 2009b).
Clinical microbiologists have two reasons for being inter-
ested in plant extracts with antimicrobial activity. In the first
place, it is very likely that the phytochemicals found have a
role in the arsenal of antimicrobial agents, since scientists
know that the useful effective life of any antibiotic is limited.
In the second place, the public is increasingly aware of the
problems with the overprescription and misuse of conventional
antibiotics. A large number of compounds from plants (often
of reliable nature) are readily available without the need for
a doctor’s prescription, in drug stores and natural food stores,
where self-medication with these substances is common. The
use of plant extracts as another form of medical treatment
has gained popularity since the 1990s (Cowan, 1999).
The family Passifloraceae stands out in the Brazilian flora
because of its extensive use in phytotherapy, and the genus
Passiflora is the most found in the country. Passion fruit
belongs to the genus, and this popular name designates more
than 120 species (encountered and native) in Brazil (Barbosa,
2006).
Passiflora cincinnata Mast. is one of the wild species of the
genus that has a great potential for raw consumption, the pro-
duction of juice concentrate and utilization as functional food.
Its high commercial yield, as well as content of phytochemical
compounds, has stirred great interest in its research, besides
diversified utilization. The phytochemical characteristics
shown for this species are of interest to the food industry,
aimed at developing those with bioactive substances to meet
the needs of the consumer, and also to the pharmaceutical
industry (Wondracec, 2009), which despite continuous efforts,
has had difficulties in finding or developing new effective
drugs, with the urgency needed (Vermelho et al., 2007).
Here, were evaluated the antimicrobial potential and
antibiotic-modifying activity of hydroalcoholic extracts ofL.A. et al., Potentiation of antibiotic ac
Sciences (2016), http://dx.doi.org/10.10leaves, stems, epicarp, pulp and seeds of P. cincinnata Mast.,
against standard and multiresistant strains of Staphylococcus
aureus and Escherichia coli.2. Materials and methods
2.1. Collection and preparation of plant material
Leaves, stems and fruits (epicarp, pulp and seeds) were col-
lected in the municipality of Crato, Ceara, Brazil. The plant
material was identified, and a dried specimen was deposited
in the Herbario Caririense Dardano de Andrade-Lima of the
Cariri Regional University (URCA), Crato, Ceara, Brazil,
under identification No. HCDAL 8097.
The plant material collected was transported to the Phar-
macology and Molecular Chemistry Laboratory (LFQM),
URCA, where it was selected according to the degree of appar-
ent health (the absence of mechanical damage and fungal
spots), washed and air-dried until excess moisture was
removed. The material was then processed, according to its
physical characteristics, pulverizing it to increase the surface
in contact with the extraction solvent. The plant mass obtained
was extracted with 50% aqueous ethanol for 72 h. The extract
was filtered and then concentrated using a rotary evaporator
and warm-water bath. Afterward, the extracts were frozen
and lyophilized (Matos, 1997).
2.2. Microbiological tests
The clinical isolates used were from the Clinical Mycology
Laboratory of Universidade Federal da Paraiba, and were as
follows: standard bacterial strains S. aureus ATCC 25923
and E. coli ATCC 11105 and multiresistant bacterial strains
S. aureus 03 and E. coli 08. The aminoglycosides amikacin
and gentamicin and beta-lactams ampicillin, potassium ben-
zylpenicillin and oxacillin were utilized at a starting concentra-
tion of 5000 lg/mL. All drugs were dissolved in sterile water.
Antibacterial susceptibility was determined using the broth
microdilution method. The highest concentration of plant
extract used in the tests was 1024 lg/mL, which was obtained
by dissolving 0.010 g of each extract in 1 mL of dimethylsul-
foxide (DMSO) and diluting with sterile distilled water to a
test concentration of 100 mg/mL. The inoculum was diluted
in 10% BHI (brain heart infusion) to give a concentration of
105 CFU/mL. A volume of 100 lL of BHI and inoculum
was added to each well of a 96-well plate, followed by
100 lL of serial dilutions of extracts, at concentrations oftivity by Passiflora cincinnata Mast. front of strains Staphylococcus aureus and
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(Javadpour et al., 2013). Bacterial growth was assessed using
resazurin to determine the minimum inhibitory concentration
(MIC). MIC was defined as the lowest concentration at which
no growth was observed according to NCCLS guidelines
(2005). In the drug-modifying test, the method proposed by
Coutinho et al. (2008) was utilized, where the extracts were
tested using a subinhibitory concentration (MIC/8). A 100-
lL mixture of 10% BHI, inoculum and extract was added to
each well in the alphabetic order of the plate. Next, 100 lL
of the drug were added to the first well, followed by 2-fold
serial dilutions from the next to the last well. The concentra-
tions of aminoglycosides and beta-lactams varied gradually
from 5000 to 1.22 lg/mL.
3. Results
The hydroalcoholic extracts of leaves, stems, epicarp, pulp and
seeds of P. cincinnata Mast. did not show antimicrobial activ-
ity of clinical relevance against the bacterial strains S. aureus
ATCC 25923 and E. coli ATCC 11105, where the minimum
inhibitory concentration was equal to or greater than
1024 lg/mL.
The extracts were tested at a subinhibitory concentration
for antibiotic-modifying activity using the multiresistant
strains S. aureus 03 and E. coli 08 treated with antibiotics of
the aminoglycoside and beta-lactam classes. They showed sig-
nificant effects compared to the activity of the antibiotic alone,
in accordance with the resistance profile of the strains utilized
(Table 1).
In analyzing the number of events where MIC was modified
by the combination of antibiotic and extract, it was seen that
S. aureus 03 showed 13 events of MIC modulation, while
E. coli 08 showed only 4 events, taking into consideration all
extracts combined with the two classes of antimicrobials tested
(Fig.1). It is important to point out that among the 17 events
observed, 14 were activities synergistic with the expected effect
of the antibiotic and only 3 events showed activity antagonistic
with the effect of ampicillin, namely with the strain S. aureus
03 and extracts of stems, epicarp and seeds of P. cincinnata
(Tables 2–6). The comparative analysis between the classes
of antibiotics tested shows that the beta-lactams surpassed
the aminoglycosides in the number of synergistic events and
also in the number of antagonistic events (Table 7).Table 1 Origin of the bacterial strains and antibiotic resis-
tance profile.
Bacteria/origin Resistance
Staphylococcus
aureus 03 Eschar
Cefadroxil/Cephalexin/Cephalothin/
Oxacillin/Penicillin/Ampicillin/Amoxicillin/
Moxifloxacin /Ciprofloxacin/Levofloxacin
Ampicillin + Sulbactam/Amoxicillin
+ Clavulanic Acid/Erythromycin/
Clarithromycin Azithromycin/
Clindamycin/Mupirocin
Escherichia coli 08
Uroculture
Ceftriaxone/Cephalothin/Cephalexin/
Cefadroxil/Cefepime/Ciprofloxacin/
Levofloxacin/Ampicillin + Sulbactam
Please cite this article in press as: Siebra, A.L.A. et al., Potentiation of antibiotic ac
Escherichia coli. Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.104. Discussion
Phytochemical assays previously performed with hydroalco-
holic extracts of the aerial parts (leaves, stems, epicarp, pulp
and seeds) established that P. cincinnata possesses the follow-
ing classes of secondary metabolites: condensed tannins, phlo-
baphenes, flavones, flavononols, flavonols, xanthones,
chalcones, aurones, flavanones, leucoanthocyanidin, catechins
and alkaloids. Since these phytoconstituents originate from the
secondary metabolism of plants, they almost always act in
plant defense against pathogens and may therefore have inter-
esting biological activities (Simo˜es et al., 2010).
Biological assays using combinations alone reveal that fla-
vonoids have a strong impact on biological systems, demon-
strating antimicrobial, antiviral, antiulcerogenic, cytotoxic,
antineoplastic, antioxidant, antihepatotoxic, antihypertensive,
hypolipidemic, antiinflammatory and antiplatelet effects
(Machado et al., 2008). The activity demonstrated in our
in vitro assays carried out with the hydroalcoholic extracts of
P. cincinnata is likely due to the action of phenolic compounds
present in all plant parts, confirming the antimicrobial activity
attributed to this class of secondary metabolites. The combina-
tion of natural products with conventional antibiotics can
exert a direct activity against many bacterial species, modulat-
ing or even increasing the activity of specific antibiotic, revers-
ing the natural resistance of the bacteria. The potentiation of
the activity or reversal of the resistance to antimicrobials,
allows the classification of these compounds as modifiers of
antibiotic activity (Coutinho et al., 2009a). The use of extracts
is interesting because they show a low possibility of the
microorganisms acquiring resistance to their action, since they
are complex mixtures, making it difficult for microbial adapta-
tion (Daferera et al., 2003).
S. aureus is one of the principal causes of infectious diseases
in humans, associated with community and hospital origins,
varying from minor infections of the skin to severe infections
such as pneumonia and septicemia (Archer and Climo, 2013;
Sugimoto et al., 2013). In the last years, the emergence of vir-
ulent strains resistant to various antibiotics, such as
methicillin-resistant S. aureus (MRSA) and methicillin resis-
tant staphylococcus (MRS), represents a major problem
worldwide (Sugimoto et al., 2013; Zetola et al., 2005). Histor-
ically, the resistance to penicillinase-stable penicillins has been
called ‘‘resistance to methicillin.” In the case of S. aureus resis-
tant to oxacillin and coagulase-negative staphylococci (MRS),
other b-lactams/b-lactamase inhibitors, cephems and car-
bapenems, appear to be active in vitro, but are clinically inef-
fective. The results for these drugs should be reported as
resistant, or should not be reported. This is due to the fact that
the majority of the reported cases of MRS infections have not
responded adequately to therapy with b-lactams, or because
relevant clinical data have not yet been presented documenting
the clinical efficacy of these agents under these conditions
(CLSI/NCCLS, 2005).
The bacterial strain S. aureus 03, utilized in the antibiotic-
modifying experiments with the combination of aminoglycosides
or beta-lactams and hydroalcoholic extracts of P. cincinnata is
classified as a MRSA, showing a resistance profile for the
antimicrobials utilized. The modulatory effect shown by the
extracts, especially on the antimicrobials oxacillin and
benzylpenicillin, was not capable of altering the phenotype oftivity by Passiflora cincinnata Mast. front of strains Staphylococcus aureus and
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Figure 1 Comparison of number of drug modifying events with extracts of P. cincinnata when combined with aminoglycosides and
beta-lactams, against the strains S. aureus 03 and E. coli 08.
Table 2 Antibiotic modifying activity of the hydroalcoholic
extract of leaves of Passiflora cincinnata Mast. in combination
with aminoglycosides and beta-lactams.
Antibiotics Staphylococcus aureus 03 Escherichia coli 08
Control +EHFPC Control +EHFPC
Amikacin 312.5 312.5 156.25 39.06
Gentamicin 312.5 78.125 39.06 39.06
Ampicillin 156.25 156.25 312.5 312.5
Benzylpenicillin 2500 625 2500 2500
Oxacillin 2500 625 P5000 2500
* HELPC: hydroalcoholic extract of the leaves of Passiflora
cincinnata Mast.
Table 3 Antibiotic modifying activity of the hydroalcoholic
extract of seeds of Passiflora cincinnata Mast. in combination
with aminoglycosides and beta-lactams.
Antibiotics Staphylococcus aureus 03 Escherichia coli 08
Control +EHSPC Control +EHSPC
Amikacin 625 625 78.125 78.125
Gentamicin 625 625 312.5 312.5
Ampicillin 78.125 312.5 312.5 312.5
Benzylpenicillin P5000 1250 P5000 2500
Oxacillin 2500 625 2500 2500
* HESPC: hydroalcoholic extract of seeds of Passiflora cincinnata
Mast.
Table 4 Antibiotic modifying activity of the hydroalcoholic
extract of stems of Passiflora cincinnata Mast. in combination
with aminoglycosides and beta-lactams.
Antibiotics Staphylococcus aureus 03 Escherichia coli 08
Control +EHHPC Control +EHHPC
Amikacin 625 625 78.125 78.125
Gentamicin 625 625 312.5 312.5
Ampicillin 78.125 312.5 312.5 312.5
Benzylpenicillin 2500 625 2500 2500
Oxacillin 2500 625 2500 2500
* HEStPC: hydroalcoholic extract of stems of Passiflora cincinnata
Mast.
Table 5 Antibiotic modifying activity of the hydroalcoholic
extract of epicarp of Passiflora cincinnataMast. in combination
with aminoglycosides and beta-lactams.
Antibiotics Staphylococcus aureus
03
Escherichia coli 08
Controle +EHEPC Controle +EHEPC
Amicacina 312.5 312.5 78.125 78.125
Gentamicina 625 625 312.5 312.5
Ampicilina 78.125 312.5 312.5 312.5
Benzylpenicilina 2500 625 2500 2500
Oxacilina 2500 625 2500 2500
* EHEPC: extrato hidroalcoo´lico do epicarpo de Passiflora
cincinnata Mast.
4 A.L.A. Siebra et al.this strain from resistant to sensitive, but there was a decrease in
MIC enough to impede the growth of the pathogen. The num-
ber of events was relevant, especially because at least 10 syner-
gistic activities were repeated, in all the combination of
extracts and antimicrobials in this test.Please cite this article in press as: Siebra, A.L.A. et al., Potentiation of antibiotic ac
Escherichia coli. Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.10Considering that Gram-positive bacteria have a cell wall
that is chemically less complex and has a lower lipid level than
do Gram-negative bacteria (Loguercio et al., 2005), it istivity by Passiflora cincinnata Mast. front of strains Staphylococcus aureus and
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Table 6 Antibiotic modifying activity of the hydroalcoholic
extract of pulp of Passiflora cincinnata Mast. in combination
with aminoglycosides and beta-lactams.
Antibiotics Staphylococcus aureus 03 Escherichia coli 08
Control +EHPpC Control +EHPpC
Amikacin 312.5 312.5 78.125 19.531
Gentamicin 312.5 312.5 39.06 39.06
Ampicillin 156.25 156.25 625 625
Benzylpenicillin 2500 625 2500 2500
Oxacillin 2500 2500 2500 2500
* HEPPC: hydroalcoholic extract of pulp of Passiflora cincinnata
Mast.
Table 7 Comparative study of antimicrobial drug activity of
the pharmacological classes of aminoglycosides and beta-
lactams when combined with hydroalcoholic extracts of aerial
parts of P. cincinnata, with regard to their synergistic and
antagonistic effects.
Antimicrobials S. aureus 03 E. coli 08 Total
Aminoglycosides
Amikacin 0 2 synergism 2
Gentamicin 1 synergism 0 1
BETA-Lactams
Ampicillin 3 antagonisms 0 3
Benzylpenicillin 5 synergismo 1 synergism 6
Oxacillin 4 synergisms 1 synergism 5
Total 13 04 17
Potentiation of Antibiotic Activity by Passiflora cincinnata Mast. 5suggested that the structure of S. aureus (Gram-positive bac-
terium) can be a facilitating factor in the synergistic activity
of the hydroalcoholic extracts of P. cincinnata with aminogly-
cosides and beta-lactams. Studies have shown that the inhibi-
tion of the growth of S. aureus can be associated with the
ability of flavonoids to complex with the bacterial cell wall,
causing rupture of the cell membrane (Cowan, 1999). There-
fore, the combination of natural products with antibiotics
favors the disintegration of bacterial cell membranes through
complexation by agents associated with this structure.
The antagonistic effect observed with the extracts of stems,
epicarp and seeds, when combined with ampicillin, can be
explained by the mixture of compounds present in crude
extracts, which contain higher amounts of metabolites capable
of decreasing the effects of active substances (Peitz et al.,
2003).
The emergence of MRS strains as serious human pathogens
and their growing prevalence in nosocomial infections increase
the necessity to identify and limit their spread. The detection of
methicillin-resistant Staphylococcus strains is complex; there
are difficulties in identifying them with precision, especially
because resistance is frequently heterogeneous and its expres-
sion is affected by different factors (Chambers, 1997). Contin-
uous efforts are needed to understand the epidemiological
changes in S. aureus in humans and animals, not only for ade-
quate and effective antimicrobial treatment to control the
infection but also to follow the evolution of the species
(Stefani et al., 2012).Please cite this article in press as: Siebra, A.L.A. et al., Potentiation of antibiotic ac
Escherichia coli. Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.10E. coli is one of the best characterized model organisms.
Some of its variants have been the key to advances in genetics,
molecular biology, physiology and biochemistry, where they
have the interesting characteristic of being commensal in the
intestine of vertebrates and at the same time pathogens capable
of killing more than 2 million people per year, through intesti-
nal and extra-intestinal diseases (Kosek et al., 2003; Russo and
Johnson, 2003). Therefore, it is the perfect candidate for the
study of the transition between commensalism and pathogenic-
ity (Pinheiro et al., 2007) or, more broadly, how the strict con-
nection between bacteria and their host can fluctuate between
mutualism, commensalism and opportunistic pathogen
(Tenaillon et al., 2010).
E. coli is a facultative anaerobic, non-sporulating, Gram-
negative bacterium, found in the intestinal microbiota, where
it is the predominant microorganism in the gastrointestinal
tract. Gram-negative bacteria have many resources of resis-
tance, such as the production of beta-lactamases, which inacti-
vate antibiotics that are resistant to the action of the majority
of bacterial enzymes (Koneman et al., 2008). There is even a
large variety of mechanisms of resistance to b-lactams, one
of the most important being the production of beta-
lactamases, which are enzymes capable of hydrolyzing the b-
lactam ring of penicillins, cephalosporins and other related
antimicrobials, resulting in their inactivation. Of special inter-
est is extended-spectrum beta-lactamase (ESBL), mainly pro-
duced by some species of Gram-negative bacteria (Francisco
and Jea, 2011). The first report of ESBL-producing strains
occurred in Frankfurt, Germany, in 1983, where enzymes of
the SHV type were isolated from Klebsiella pneumoniae and
E. coli. The analysis of these strains demonstrated that resis-
tance was due to a transferable beta-lactamase plasmid,
derived from SHV-1, which was called SHV-2 (Sousa-Ju´nior
et al., 2004).
ESBL-producing strains are generally multiresistant, and
ESBL-producing enterobacteria have been isolated more often
in samples from hospitalized patients, but they can also be
found in samples of community origin (Sousa-Ju´nior et al.,
2004). Despite the apparent in vitro sensitivity to various
antimicrobials, patients with infections with ESBL strains
may not respond to therapy with beta-lactams. Generally,
these strains exhibit co-resistance to aminoglycosides, due to
the use of these agents being based on the antibiogram
(Sousa-Ju´nior et al., 2004).
A comparison of the results for E. coli versus S. aureus
revealed a difference in drug susceptibility, explained by the
difference in the composition of their membranes. The outer
membrane of Gram-negative bacteria has a barrier resistant
to the penetration of various antimicrobial agents, where it
also harbors a periplasmic space containing enzymes capable
of inactivating some antibiotics (Vermelho et al., 2007). This
could account for the difference in vulnerability exhibited by
the microorganisms, since drug-modifying activity with S. aur-
eus was seen in 13 events of MIC reduction between synergism
and antagonism, against aminoglycosides and beta-lactams.
On the other hand, the combination of the same antimicrobials
with P. cincinnata extracts against the ESBL-producing mul-
tiresistant strain E. coli 08, showed efficacy in only 4 events
and only for the extracts of leaves, pulp and seeds, all with syn-
ergistic activity. Extracts of stems and bark did not produce
any effect compared to controls.tivity by Passiflora cincinnata Mast. front of strains Staphylococcus aureus and
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6 A.L.A. Siebra et al.Multiresistance in Gram-negative bacteria occurs through
the accumulation of resistance plasmids or by horizontal gene
transfer, associated with an outer membrane barrier of low
permeability, with an efficient complex of efflux pumps (cap-
able of pumping out of the bacteria more than one type of
drug), combined with various specific mechanisms of resis-
tance (Nikaido, 2009). In addition, the susceptibility of the
bacterial cells to antibiotics can be affected by their physiolog-
ical state. An important consequence of this phenomenon is
the discovery of ‘‘persistent” cells, revealing that even high
concentrations of antibiotics do not kill the whole bacterial
population, leaving a resistant population that is genetically
identical to the susceptible cells (Tikhonova et al., 2007).
We therefore conclude that the hydroalcoholic extract of
P. cincinnata has potential as an antibacterial agent when
combined with drugs that are little effective in the treatment
of various human diseases but are often utilized by the public
in general. Its profile of action is thereby altered by decreasing
the MIC of conventional antibiotics, where this plant extract
can be developed as a new therapeutic weapon, potentiating
aminoglycosides and beta-lactams, which are not very effective
in the treatment of infections caused by MRSA and ESBL
strains.
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